Welcome to our dedicated page for Kairos Pharma, LTD. SEC filings (Ticker: KAPA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kairos Pharma SEC filings document regulatory disclosures for a clinical-stage oncology company, including Form 8-K reports on clinical updates for ENV-105 in metastatic castration-resistant prostate cancer and non-small cell lung cancer. The filings also record material agreements tied to oncology asset rights, including license novations involving Cedars-Sinai patents and TRC105/CD105 technology.
Other filings describe proposed oncology asset transactions, executive and director equity compensation under the 2023 Equity Incentive Plan, cash bonus approvals, furnished press releases, and exhibit materials. These records outline governance actions, capital-stock award mechanics, intellectual-property and license arrangements, and event disclosures relevant to Kairos Pharma's development-stage business.
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company advancing immunotherapy and cell therapy candidates. As of June 30, 2025, the company held $3,034 in cash and cash equivalents and reported a six-month net loss of $2,684. Operating expenses for the six months were $2,722, driven by $989 of R&D (including Phase 2 ENV105 prostate and Phase 1 ENV105 lung trials and a Phase 1 for KROS201) and $1,733 of general and administrative costs. Accumulated deficit was $11,499 and shareholders' equity was $5,997.
The company raised capital in 2025 via a January PIPE (net proceeds $3,058) and draws under a $30,000 Equity Line of Credit (ELOC), selling 3,510,000 ELOC shares for aggregate net proceeds of $3,903 as of the filing and an additional 3,000,000 ELOC shares for $3,693 in July 2025. Deferred offering costs totaled $1,692. Vendor advances, net, were $1,717 with significant amortization in the period. The company states current cash is expected to fund operations for at least 12 months, but continues to depend on future financings to execute its development plan.